Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
Volume 4.26M
Average 2.07M
QGEN Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Qiagen N.V.NYSE: QGEN
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin widens to 19.3%
Net margin was 19.3% in Q2 FY2026, up 1.3 pp from a year earlier. On a trailing-twelve-month basis it was 19.5%, up 1.2 pp year over year. Over 3 fiscal years it widened by 0.6 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 11 analysts of 23.9% for the fiscal year ending Dec 2026, up from 20.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 19.3%+5.5 pp QoQ
- Last fiscal yearDec 2025
- 20.3%+16.1 pp YoY
- LTMJun 2026
- 19.5%+1.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.3 pp | -0.2 pp | -1.5 pp |
| 1 year | +16.1 pp | +3.5 pp | -12.6 pp |
| 3 years | +0.6 pp | +5.5 pp | +4.9 pp |
| 5 years | +6.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 20.3%
- Year-over-year change
- +16.1pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.3% | +16.1pp |
| FY2024 | 2024-12-31 | 4.2% | -13.1pp |
| FY2023 | 2023-12-31 | 17.4% | -2.4pp |
| FY2022 | 2022-12-31 | 19.8% | -3.0pp |
| FY2021 | 2021-12-31 | 22.8% | — |
Net Margin vs competitors
How QGEN compares with its peers on the latest reported figures
- QGEN's LTM Jun 2026 net margin of 19.5% is the 2nd highest of the 11 companies compared; the peer median is 8.4%.
- Its year-over-year change of +1.2 pp is the 6th highest of 11, against a peer median of +1.3 pp.
- Over three fiscal years its change of +0.6 pp compares with a peer median of -9.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jul 2026 | 19.5% | +1.6 pp | +0.4 pp | |
| LTM Jun 2026 | 19.5% | +1.2 pp | +0.6 pp | |
| LTM Sep 2026 | 16.9% | +2.5 pp | -12.3 pp | |
| LTM Sep 2026 | 15.0% | -0.1 pp | -0.4 pp | |
| LTM Sep 2026 | 14.0% | +7.6 pp | -10.1 pp | |
| LTM Jun 2026 | 8.6% | -3.9 pp | +158.9 pp | |
| LTM Jul 2026 | 8.2% | -2.1 pp | -8.7 pp | |
| LTM Jun 2026 | 5.3% | +7.3 pp | -16.6 pp | |
| LTM Jun 2026 | -2.0% | -4.3 pp | -12.0 pp | |
| LTM Sep 2026 | -10.8% | +1.0 pp | +25.4 pp | |
| LTM Jun 2026 | -37.1% | +53.1 pp | -95.3 pp | |
| Peer median (excluding QGEN) | 8.4% | +1.3 pp | -9.4 pp | |
Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.25B | 2.14B | 1.97B | 1.98B | 2.09B |
| Cost of Revenue | 800.84M | 756.96M | 731.62M | 1.01B | 798.5M |
| Gross Profit | 1.45B | 1.38B | 1.23B | 967.35M | 1.29B |
| Gross Margin | 64.4% | 64.7% | 62.8% | 48.9% | 61.8% |
| Research & Development | 189.96M | 189.86M | 198.51M | 193.49M | 187.52M |
| Selling, General & Admin | 584.47M | 603.95M | 579.17M | 564.36M | 583.67M |
| Operating Expenses | 820.74M | 853.1M | 823.75M | 869.64M | 771.19M |
| Depreciation & Amortization | 214.93M | 208.4M | 205.34M | 203.27M | 193.75M |
| EBITDA | 895.24M | 779.36M | 688.56M | 368.26M | 717.27M |
| EBITDA Margin | 39.8% | 36.4% | 35.0% | 18.6% | 34.3% |
| Operating Income | 630.08M | 531.46M | 409.94M | 97.71M | 520.31M |
| Operating Margin | 28.0% | 24.8% | 20.9% | 4.9% | 24.9% |
| Interest Income | 9.56M | 32.76M | 78.99M | 68.02M | 64.32M |
| Interest Expense | 54.48M | 58.36M | 53.41M | 43.84M | 33.26M |
| Other Income / Expenses | (4.25M) | (18.86M) | 19.87M | 23.44M | (30.04M) |
| Income Before Tax | 625.83M | 512.6M | 429.81M | 121.15M | 490.27M |
| Pre-Tax Margin | 27.8% | 23.9% | 21.9% | 6.1% | 23.5% |
| Income Tax Expense | 113.23M | 89.39M | 88.51M | 37.56M | 65.39M |
| Net Income | 512.6M | 423.21M | 341.3M | 83.59M | 424.88M |
| Net Margin | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
| EPS (Basic) | 2.52 | 2.08 | 1.67 | 0.39 | 2.04 |
| EPS (Diluted) | 2.47 | 2.05 | 1.65 | 0.38 | 2.04 |
| Weighted Avg Shares | 221.14M | 220.75M | 217.49M | 216.44M | 207.94M |
| Weighted Avg Shares (Diluted) | 225.07M | 223.23M | 217.49M | 218.48M | 207.94M |
Qiagen N.V.
NYSE:QGEN
Intrinsic Alpha fair value
Locked
Current Price
$49.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.